Citigroup’s Belite Bio BLTE Stock Holding History
Bought
Maintained
Sold
Other funds holding BLTE
DGM
Citigroup's BLTE Position: Q3 2026 in Review
Citigroup sold out of Belite Bio (BLTE) in Q3 2026, closing a stake of 47 shares — an estimated $7.24K sold.
Citigroup first reported a position in BLTE in Q1 2025 and held it in 5 quarters. The position peaked at $342K in Q4 2025. 96 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.
- Citigroup reported no remaining Belite Bio position as of Q3 2026 after selling out during the quarter.
- Citigroup sold 47 Belite Bio shares in Q3 2026, an estimated $7.24K.
- Citigroup first reported a position in Belite Bio in Q1 2025 and held it in 5 quarters.
- Citigroup's Belite Bio position peaked at $342K in Q4 2025.
- 96 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.